Equities

Syncom Formulations (India) Ltd

SYNCOMF:NSI

Syncom Formulations (India) Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)22.71
  • Today's Change0.31 / 1.38%
  • Shares traded11.54m
  • 1 Year change+162.54%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 11:28 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the development, manufacturing & sale of pharmaceutical products and services& trading of commodities and renting of properties. The Company manufactures and markets more than 200 pharmaceutical formulation products in various dosage forms, like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections and Dry Vial injections, Dry Syrups, Ointments and Inhalers. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Albendazole Oral Suspension USP 100mg, Cetirizine Oral Solution BP, Clotrimazole Cream USP, Compound Benzoic Acid Ointment BP, and others.

  • Revenue in INR (TTM)2.91bn
  • Net income in INR285.50m
  • Incorporated1988
  • Employees802.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Remus Pharmaceuticals Ltd450.27m85.03m14.21bn38.00150.8754.68158.1831.5515.9815.9890.2544.09------11,849,290.00--------52.39--18.88--1.35--0.2933--82.17--151.14------
Lincoln Pharmaceuticals Ltd5.92bn979.63m14.57bn1.70k14.87--13.342.4648.9148.91295.69--------3,483,600.00--13.95--16.5451.9250.6516.5414.71--60.93--3.4413.769.6627.9913.8821.543.71
Kopran Ltd6.37bn592.79m15.61bn358.0022.29--21.442.4514.5314.53150.01--------17,794,040.00--8.47--12.2336.0332.939.318.89--27.17--25.4111.5411.4287.1116.2312.53--
JG Chemicals Ltd-100.00bn-100.00bn16.17bn56.00-------------------------------------------------14.90---43.84------
Beta Drugs Ltd2.96bn364.37m16.48bn315.0045.2210.4935.655.5737.9037.90307.60163.431.314.514.17--16.1015.1023.9122.2338.7339.7712.3212.381.5117.810.0654--30.2135.0118.6235.29-10.89--
Zota Health Care Ltd1.98bn-242.34m16.59bn445.00----3,553.168.37-9.27-9.2776.32--------4,452,605.00---1.38---1.8549.8635.95-12.23-1.33---2.87----28.9616.08-148.54--39.850.00
Windlas Biotech Ltd6.61bn596.01m17.97bn1.15k30.14--23.632.7228.5228.52316.58--------5,730,702.00--------37.39--9.01----48.16----22.97--36.51------
Sigachi Industries Ltd4.10bn594.65m18.18bn991.0034.00--25.554.431.601.6010.97--------4,136,886.00--14.77--19.5752.3350.3014.4314.92--7.19--1.6132.0825.3431.3424.6470.35--
Hester Biosciences Ltd2.99bn193.56m20.17bn642.00101.92--53.286.7523.2623.26350.03--------4,656,698.00--6.15--7.6971.5266.647.3412.83--2.26--23.2714.4511.33-29.06-14.591.49-11.42
Panacea Biotec Ltd5.46bn-279.53m20.25bn1.15k----266.613.71-4.58-4.5889.84--------4,761,763.00--10.26--16.5360.2450.27-5.2024.87---17.30--0.0021.574.1396.47--74.65--
Syncom Formulations (India) Ltd2.91bn285.50m20.94bn802.0068.35--62.577.200.3260.3262.99--------3,626,019.00--7.50--10.2339.5334.109.829.38--7.67----17.457.1226.1317.95----
Amrutanjan Health Care Ltd4.27bn425.73m22.57bn635.0053.12--46.235.2814.7114.71147.56--------6,726,040.00--16.22--20.1249.6153.099.9713.23--212.51--18.9510.9610.7112.9012.4626.9316.43
Themis Medicare Ltd4.08bn500.16m23.77bn1.54k47.57--38.575.835.435.4344.31--------2,648,322.00--11.12--16.4663.5160.3212.2614.96------7.597.7415.75-23.51--26.73--
IOL Chemicals and Pharmaceuticals Ltd.20.72bn1.19bn28.29bn2.78k23.86--15.301.3720.2020.20353.05--------7,461,253.00--14.91--19.4533.9634.545.7212.00--10.06--10.59-3.804.82-3.39-10.7035.27--
Dishman Carbogen Amcis Ltd24.16bn-2.48bn28.62bn1.13k----165.731.18-15.81-15.81154.06--------21,344,260.00---0.3986---0.488879.3073.83-10.27-1.54---0.7216----8.414.91-414.93---0.3175--
Data as of Sep 20 2024. Currency figures normalised to Syncom Formulations (India) Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Motilal Oswal Asset Management Co. Ltd.as of 31 Aug 20246.40k0.00%
Data from 31 Aug 2024 - 31 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.